摘要
近年来对免疫应答机制和同种异体移植物排斥方面的认识不断深入,使得肾移植免疫抑制有了创新和发展。单克隆抗体作为一种新型免疫抑制剂,在治疗和预防肾移植急性排斥方面取得了较好疗效。Ⅲ期临床试验中已经证实了一些单克隆抗体在预防急性排斥方面的效果,而且已成为免疫抑制治疗方案的一部分;另外一些现在正在试验,而且已经显示在免疫抑制方面的潜能,这些单克隆抗体有望成为促进器官移植特异性抗原耐受的有效制品。
In the past few years, Remarkable advances have been made in understanding the mechanisms of immune recognition and allograft rejection, leading to the development of innovative strategies in the field of renal transplantation. Monoclonal antibodies（mAbs） have emerged as a new class of immunosuppressive agents,which appear to be effective in both the treatment and the prevention of acute rejeetion.Some of these mAbs have already confirmed to be efficacy in preventing acute rejection in chnical phase Ⅲ studies, and to be part of the well-established immnnesuppressive regimens. Other recently developed mAbs are currertdy being tested, and show encouraging immunosuppressive potentiality. These mAbs could become an effective method to promote the holy grail of solid-organ transplantation and antigen-specific tolerance.
出处
《医学综述》
2008年第5期752-754,共3页
Medical Recapitulate
关键词
单克隆抗体
免疫抑制
肾移植
Monoclonal antibodies
lnnnunosuppression
Renal transplantation
